Concord Biotech Limited (CONCORDBIO) Share Price
NSE · Healthcare · Biotechnology · ISIN INE338H01029
Key metrics
- Market Cap
- ₹15,495 Cr
- P/E Ratio
- 50.98
- EPS
- 29.05
- Book Value
- 192.62
- P/B Ratio
- 7.83
- ROE
- 12.95%
- ROCE
- 15.11%
- Debt / Equity
- 0
- Net Margin
- 24.93%
- Revenue Growth
- -11.31%
- Profit Growth
- -29.8%
- Dividend Yield
- 0.51%
- 52W High
- ₹1,730.00
- 52W Low
- ₹987.00
- Market Cap Band
- mid cap
- Face Value
- 1
Ratios computed from the annual results period ending 2026-03-31.
About Concord Biotech Limited
Concord Biotech Limited, a, biopharma company, engages in the research and development, manufacture, and sale of pharmaceutical products in India and internationally. It operates through Active Pharmaceutical Ingredients (APIs) and Formulations segments. The company provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. It also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, voclosporin, and pimecrolimus for immunosuppressants therapeutic segment; and temsirolimus, everolimus, romidepsin, doxorubicin, mitomycin, midostaurin, and dactinomycin for oncology therapeutic segment. In addition, the company provides mupirocin, mupirocin calcium, polymyxin B sulfate, fidaxomicin, vancomycin hydrochloride, daptomycin, fusidic acid, colistimethate sodium, and teicoplanin for anti-bacterial applications; anidulafungin, caspofungi acetate, micafungin sodium, and nystatin for anti-fungal therapeutic segment; and lovastatin and pravastatin sodium for other applications. Further, the company provides contract research and manufacturing services in the areas of fermentation and semi-synthesis products. Concord Biotech Limited was incorporated in 1984 and is based in Ahmedabad, India.
- Headquarters
- Ahmedabad, India
- Employees
- 1,624
- Promoter Holding
- 72.48%
The full Concord Biotech Limited analysis
Create a free account to open the complete CONCORDBIO deep-dive — fourteen tabs of fundamental, technical, institutional and ownership data.
- 10-year financialsIncome statement, balance sheet and cash flow, year by year.
- Valuation & fair valueFair-value estimates, quality scores and a value grade.
- Charts & technicalsCandlestick charts, RSI, MACD, Supertrend and detected patterns.
- Shareholding historyPromoter, FII, DII and public holdings across every quarter.
- Ace investor holdingsWhich well-known investors hold it, and how their stake changed.
- Deals & insider tradesBulk and block deals, insider transactions and mutual-fund holdings.